A number of recent studies have demonstrated that cellular responses to tumor necrosis factor (TNF) mediated by the p55 and the p75 TNF receptors are distinct. To evaluate the relative in vivo toxicities of wild-type TNFot (wtTNFc~) and a novel p55 TNF selective receptor agonist, healthy, anesthetized baboons (Papio sF) were infused with a near-lethal dose of either wtTNFc~ or a TNFc~ double mutant (dmTNFo 0 that binds specifically to the p55, but not to the p75, TNF receptor. Both wtTNFc~ and dmTNFcr produced comparable acute hypotension, tachycardia, increased plasma lactate, and organ dysfunction in Papio. However, administration of wt TNFo~ produced a marked granulocytosis and loss of granulocyte TNF receptors, whereas little if any changes in neutrophil number or cell surface TNF receptor density were seen after dmTNFcx mutant administration. Infusion of dmTNFcx resulted in a plasma endogenous TNFc~ response that peaked after 90-120 min. We conclude that selective p55 TNF receptor activation is associated with early hemodynamic changes and the autocrine release of endogenous TNFc~. Significant systemic toxicity results from p55 TNF receptor activation, but the role of the p75 TNF receptor in systemic TNF toxicity requires further study.
T
NFc~ is a pleiotropic cytokine with varying immunologic and inflammatory host defense activities. The in vitro actions of TNFc~ include cytotoxicity of some tumor cell lines, antiviral activity, fibroblast and lymphocytic cell proliferation, and endothelial cell activation (for a review see reference 1). In certain transplantable tumors in mice, TNFc~ causes hemorrhagic necrosis in vivo (2) . Because of its potential as an antineoplastic agent, recombinant TNFo~ has been administered to patients with malignancies in several clinical trials. Whereas systemic administration of >200 #g/m 2 of TNFc~ has not produced the expected potent and general antitumor activity (3), such infusions were found to produce unwelcome fever and hemodynamic changes (4) . Similarly, when administered to experimental animals in relativdy greater quantities, TNFcr induced shock and mortality (5, 6) . The continued interest in the antitumor activity of TNFot is supported by the results obtained with high-dose, TNFc~ perfusions combined with a chemotherapeutic agent (7).
Recent reports on cellular studies have suggested that binding of TNFoe to its two cellular receptors, p55 and p75, elicits distinct biological responses. For example, human umbilical vein endothelial cells express both TNF receptor types, but TNFo~-induced cell adhesion and expression of intercellular adhesion molecule 1, E-selectin and vascular cell adhesion molecule 1 were found under exclusive p55 receptor control (8) . TNF binding to p55 TNF receptor also confers antiviral activity in hepatocytes and IFN-'y primed fibroblasts (9) . Tartaglia et al. (10) reported that p55 mediated apoptosis in sensitive cell lines and induced manganese superoxide dismutase, whereas p75 activated thymocyte proliferation and generation of cytotoxic T cells.
Controversy exists whether the shock responses to TNFo~ in vivo are mediated by binding to p55 or p75. Historically, the relatively low systemic toxicity of human TNFol in mice has been attributed to the fact that human TNFo~ only binds the mouse p55 TNF receptor (11, 12) . The lethal dose of human TNFc~ in the mouse is in excess of 1 mg/kg body weight (BW) 1, whereas murine TNFc~ causes death with doses as low as 10 #g/kg BW (13) . Thus, a TNFol agonist that binds to p55 but not p75 in humans might produce less pronounced systemic toxicity than wild-type TNFol (wtTNFo 0, while retaining antitumor and antiviral activities. Van Ostade et al. (14) have recently shown that a mutant TNFo~ exclusively binding to the human p55 receptor has antitumor activity against a sensitive human tumor cell line growing as a solid tumor in nude mice without any associated toxicity. However, recent studies using p55-deficient mice showed that TNF binding to p55 was required for its systemic toxicity (15, 16) .
Here we present a study of the relative in vivo toxicity in baboons of human wtTNFce compared with that of a TNFce mutant which binds with wild-type activity to human p55, but does not bind to p75. This TNFce mutant was previously generated by introducing two point mutations replacing Arg 32 by Trp, and Ser s6 by Thr (identified as a double mutant TNFce [dmTNFce]) (17) . dmTNFol also binds selectively to the baboon p55, but not to p75, whereas wtTNFce binds to both baboon TNF receptors. When administered to healthy Papio at a dose of 100/~g/kg BW, dmTNFol and wtTNFce produced comparable cardiovascular disturbances and tissue injuries. These data demonstrate that the p55 TNF receptor has an important role in systemic TNF toxicity.
Materials and Methods
The generation of a dmTNFce mutant specific for the human p55 receptor has been reported (17) . wtTNFc~ and dmTNF~ were purified by sequential gel filtration (Q-Sepharose, Pharmacia, Uppsala, Sweden) and ion exchange chromatography (Mono-S; LKB-Pharmacia) as described in reference 17 to yield an electrophoretically pure protein preparation. The identity of the TNFcx preparations was confirmed by amino acid composition analyses or ion spray mass spectrometry. Samples were diluted in sterile, endotoxinfree, physiologic saline to a final concentration of 500/~g/ml. Endotoxin content of the final preparations was <14 EU/mg protein.
Solid-phase Radioligand
Binding Assay. To demonstrate that receptor type specificities of the human wild-type TNFc~ and mutant TNFc~ were maintained in Papio, solid-phase radioligand binding studies were performed. HL60 cells were cultured and lysed with Triton X-100 as previously described (18) . Baboon buffy coats were obtained from 100 ml of venous blood from Papio anticoagulated with EDTA; cells were subsequently pelleted and frozen at -70~ Cell pellets containing ,,~10 s leukocytes were resuspended in 1.0 ml of PBS, pH 7.4, containing a cocktail of protease inhibitors (19) and diluted with an equal volume of the same buffer containing 2% Triton X-100. After extraction overnight at 4~ the samples were clarified by centrifirgatinn and immediately used for radioligand binding assay or stored at -80~ 96-well microtiter phtes were coated with affxnity-purified polyclonal antibodies (10/~g/ml in PBS) raised against recombinant 1 Abbreviations used in this paper: BW, body weight; dmTNFa, double mutant TNFce; PBS-A, PBS and 0.1% sodium azide; wtTNFce, wildtype TNFce.
soluble human p55 and p75 (8) . After blocking with 1% defatted milk powder in 50 mM Tris, 140 mM NaC1, 5 mM EDTA, 0.001% Kathon MW/WT for 1-2 h at room temperature, HL60 cell extract (2.3 x 10 s cells/nil) or baboon buffy coat extract (5 x 107 leukocytes/ml) were added (100 #l/well) and incubated overnight at 4~ The wells were then incubated with 15 ng/ml human I:sITNFc~ (sp act 0.3-1.0 x 10 s cpm/#g [19] Study Protocol. After an overnight fast, animals were initially anesthetized with ketamine (10 mg/kg intramuscularly) and anesthesia was thereafter maintained by intravenous administration of sodium pentobarbital at 3-5 mg/kg BW/h i.v. The animals were instrumented for invasive monitoring as described previously (20, 21) .
After baseline blood sampling and a waiting period of at least an hour to allow equilibration, 100/zg/kg BW of either wtTNFcr (n = 3) or dmTNFa (n = 3) were administered via the femoral vein as a bolus injection. An additional three baboons received no injections and served as instrumented controls. Arterial blood samples were obtained at 0.5, 1, 3, 5, 10, 15, 30, 60, 90, and 120 min, at hourly intervals through 8 h, and again at 24, 48, and 96 h for pharmacokinetic and blood chemistry analyses. The investigators caring for the animals were blinded to treatment. Leukocyte and thrombocyte counts were measured on venous blood anticoagulated with EDTA by flow cytometric, light scatter, and Coulter counter analyses, respectively, as previously reported (20) . Prothrombin and partial thromboplastin times were measured by the clinical laboratories at the Animal Medical Center (New York). TNF receptors on granul'ocytes were quantitated by cytofluorometry using biotinylated TNFa and PE-conjugated streptavidin. Briefly, baboon blood was anticoagulated with Na-EDTA. Erythrocytes were lysed with a bicarbonate-buffered (pH 7.2) ammonium chloride solution. Leukocytes were recovered by centrifugation and washed with PBS containing 0.1% sodium azide (PBS-A). Specific staining was determined with 1.0 #g/ml biotinylated, human TNFc~ whereas nonspecific staining was determined with biotinylated TNFc~ plus 100-fold excess, unlabeled human TNFcr After incubation on ice for 15 min, cells were washed with PBS-A and incubated with 0.5/~g/ml streptavidin-conjugated PE for 15 min on ice. Cells were then washed and resuspended in PBS-A for flow cytofluorometric analysis. For each experiment, the flow cytometer photomultiplier gain was standardized using a single lot of PE-conjugated beads. Mean channel fluorescence (>570 nm) of forward and side angle light scatter-gated granulocytes was assessed. Data are presented as the difference (linear units) between mean channel fluorescence intensities of specifically and nonspecifically stained cells.
The plasma fraction of additional EDTA and heparinized samples was separated by centrifugation at 4~ and stored at -70~ until assayed for TNFcr and sTNFR I (p55) immunoactivity, as previously described (20, 21) . TNFc~ bioactivity was determined using the murine WEHI clone 13 cytotoxicity assay (21) . IL-6 bioactivity (R9 hybridoma proliferation) and Ib8 immunoactivity were also assayed (20, 21) . At the end of an 8-h monitoring period, all catheters were removed, and animals were awakened and returned to their cages. Blood was sampled at 24, 48, and 96 h. After the last blood sampling, baboons were sacrificed by the intravenous administration of 65 mgs/kg sodium pentobarbital. Necropsy was performed at death, and tissues were fixed in 10% buffered formalin for light microscopy.
Statistical Analyses. Values are presented as the mean + standard error. Differences in responses between baboons administered wild-type and mutant TNFc~ were analyzed by two-way analysis of variance. In some cases, differences from baseline were analyzed by one-way analysis of variance, and Dunnett's multiple range test. Significance was determined at the 95% level of confidence employing a one-tailed test. tant to human and baboon p55 and p75. Sohbilized human and baboon TNF receptors were captured on microtiter plates by coating the wells with polyclonal antibodies specific for human p55 and p75. Binding of human wild-type 12SI-TNFa to the TNF receptors was determined in the presence or absence of excess unlabeled wtTNF~ or dmTNFc~ mutant. The amount of radioactivity bound in the absence of competitor is taken as 100% and was 24,911 and 74,383 counts for the p55 from baboon PBMC and HL60 cells, respectively, and 11,077 and 20,587 counts for the p75 from baboon PBMC and HL60 cells, respectively. (~p) Binding competition to p55 (receptors from both species immobilized by antihuman p55 ann~x~dies); (bottom) binding competition to p75 (receptors from both species immobilized by antihuman p75 antibodies).
Results

Specificity of TNFcr Mutant in Papi~
in baboons, the competitive binding of wtTNFoL and dmTNFoe to p55 and p75 TNF receptors derived from a human cell line and from Papio leukocytes was compared. Detergentextracted receptors from both species were immobilized on a solid-phase coated with receptor-type-specific polyclonal antibodies that had been raised in rabbits against recombinant human receptors and that cross-reacted with the respective baboon receptors. As shown in Fig. 1, binding of 12SI-labeled wtTNFot to the immobilized human and Papio p55 TNF receptors was competitively inhibited by unlabeled wtTNFc~ or dmTNFot, whereas binding to the p75 receptors of both species was competed by wtTNFoe but not by dmTNFce.
Papio Cardiovascular and Physiologic Responses. Administration of 100 I~g/kg BW of human wtTNPcY produced significant hypotension and tachycardia in the anesthetized baboon (Fig. 2) . Cardiac output declined (data not shown) and rate (middle), mean arterial pressure, and (bottom) core temperature were all measured as described in Materials and Methods. Administration of both TNFr molecules resulted in a significant tachycardia and fails in mean arterial pressure and cardiac output. The difference in increase in core temperature in baboons treated with wtTNFot and dmTNFo~ was statistically significant. a significant rise in blood lactate concentrations was also evident (Table 1 ). The animals also developed a pyrexic response. Although none of the animals administered wtTNFot expired over the subsequent 4 d, significant organ dysfunction was observed. For example, serum creatinine and blood urea nitrogen (BUN) concentrations markedly increased over 48 h in the TNFot-treated animals indicating impairment of renal function (Table 1 ). In addition, concomitant increases in hepatic enzyme levels (serum glutamate-oxaloacetate transaminase [SGOT], serum glutamate-pyurate transaminase [SGPT]) were consistent with acute hepatocellular damage. The baboons receiving wtTNFc~ also developed a significant plasma IL-6 and IL-8 response.
Administration of dmTNFo~ at 100/~g/kg BW produced comparable degrees of hypotension and tachycardia; however, the pyrexic response was significantly less pronounced (Fig.  2) . The elevation of blood lactate and presence of renal and hepatic dysfunction were similar between the animals treated with wtTNFc~ and with dmTNFcr in the initial phase of the study, but these dysfunctions tended to be more protracted in the animals treated with dmTNFoz. One of the three animals treated with dmTNFoL became unresponsive and moribund after 48 h, and was euthanized because of animal welfare concerns.
Sham infusions had no effect on hemodynamic responses in healthy baboons (Fig. 2) , nor were there any observed changes in measures of organ function (data not shown).
Hematopoietic Responses. Administration of the wtTNFol produced a significant granulocytosis (p <0.05 at 1, 3, 4, and 5 h versus baseline; Fig. 3 ). Blood monocyte and lymphocyte numbers rapidly declined (data not shown). Despite this granulocytosis, there was an almost complete loss of total cellular TNF receptors from blood granulocytes (Fig. 3) . Unfortunately, because of the lympho-and monocytopenia induced by the TNFc~ administration, there were insufficient numbers to perform flow cytofluorometric analysis of TNF receptors upon these cells. Platelet counts declined from about 300,000/#13 to 100,000-150,000//~P 2 A, A.8 h after wtTNFc~ treatment, although prothrombin and partial thromboplastin times were only modestly affected (data not shown).
In baboons administered dmTNFo~, granulocytosis was not observed. In addition, TNF receptors on granulocytes declined only transiently and then rapidly returned to levels comparable to baseline, suggesting an important role for p75 TNF receptor in receptor shedding. Baboons treated with the dmTNFo~ exhibited a similar monocytopenia and lymphopenia as seen in animals treated with wtTNFo~. The soluble TNF p55 receptor concentrations increased in baboons treated with both wtTNFob and dmTNFo~, although concentrations were marginally higher in baboons treated with wtTNFc~. Adminis- Tofal Granulocyte Number tration of the dmTNFc~ produced a similar thrombocytopenia as seen with wtTNFc~, and had no significant effect on either prothrombin or partial thromboplastin times (data not shown). Instrumentation and the sham procedure had no effect on hematologic parameters (data not shown).
Histological Examination. Treatment of baboons with
wtTNFc~ produced only modest histopathologic changes, including hepatocellular edema in one animal. In the three baboons treated with dmTNFoe, mild hepatocellular edema was also noted. Furthermore, in the one dmTNFot-treated baboon that was euthanized for animal welfare concerns, moderate necrosis and hemorrhage of the spleen and adrenals was also observed, as well as some neutrophil margimtion and pooling in the lungs.
TNFol Pharmacokinetics. The apparent/3-phase half-life
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Van Zee et al. In baboons treated with dmTNFoe, a monophasic peak of TNFot bioactivity was observed 90-120 min after the infusion suggesting endogenous production of TNFot.
wtTNFcz immunoactivity in Papio was 61 rain (Fig. 4) . The half-life of wtTNFc* bioactivity, as determined by the WEHI cytotoxicity assay, was comparable. In contrast, the dmTNFot mutant had an apparent 3-phase half-life that was significantly longer, •169 min. Previous in vitro studies have shown that this dmTNFot does not bind to the routine p55, although its affinity for human p55 is not different than wtTNF&s affinity for p55 (16) . Thus, incubation of dmTNFot with the murine WEHI clone 13 cell does not induce cytotoxicity. However, when dmTNFot was infused into otherwise healthy baboons and plasma from such animals was coincubated with WEHI clone 13 cells, cytotoxidty was observed in plasma 90-120 rain later (Fig. 4, bottom) . Since dmTNFot is not bioactive in this assay, cytotoxicity must have resulted from another source. Coincubation of these plasma samples with either a mAb directed against human TNFot (mAb 18.1.2) or a chimeric p55, human IgG fusion protein (22), completely eliminated this cytotoxicity (data not shown), confirming that the plasma appearance of WEHI cytotoxicity was endogenous TNFol.
Discussion
In this study, administration of recombinant human TNFot at a dose of 100/~g/kg BW to the healthy baboon (Papio)
produced a 35% fall in mean arterial pressure, tachycardia, and evidence of both renal and hepatic dysfunction. These responses are key elements of systemic TNF toxicity and have also been observed in cancer patients receiving TNFot as an antitumor agent (4). In dogs receiving comparable doses of TNFot, irreversible tissue damage and mortality have also been reported (6) . Healthy baboons treated with the same dose of the p55-specific dmTNFc~ responded similarly in several respects. For example, the hemodynamic changes and organ damage were of similar magnitude in both groups of animals. In fact, one mutant TNFot-treated baboon had to be euthanized, because the animal was unresponsive and unable to eat and drink. The binding studies confirm that dmTNFot competes with wtTNFc~ for Papio p55, but not for p75. Thus, it must be concluded that the systemic toxicity of dmTNFot in Papio is a result of its binding to the baboon p55 receptor exclusively.
The more protracted signs of organ dysfunction and the histological changes in the animals treated with dmTNFoe could be the consequence of its longer pharmacologic halflife which translates into a higher persistent dose at the later phases of the experiment. The reasons for the different halflives of wtTNFc~ and dmTNFc~ are not understood, but the present results are consistent with a significant role for p75 and its soluble form in TNFc~ elimination, which might be correlated with the role of p75 in TNF receptor shedding.
One novel observation of this study was that infusion of dmTNFot induced an endogenous, drculating TNFo~ response. It is unlikely that the minute contamination of dmTNFc~ with endotoxin (14 EU/mg protein) can explain the endogenous TNFot response. The baboon is the most endotoxin-resistant of all nonhuman primates (23) , and our previous studies have demonstrated that 500/tg/kg BW of Salmonella typhosa LPS is required to produce a 1 ng/ml TNFc~ plasma response (24) , whereas the current animals received only "~150 pg/kg BW.
However, the present studies cannot exclude entirely the possibility that toxicity induced by dmTNFcz was secondary to the endogenous TNFot response. The toxicity seen is clearly due to the p55 agonist, but it cannot be distinguished whether these responses are the direct result of dmTNFot binding to p55 or are the result of the induced endogenous TNFc~ that subsequently binds to both p55 and p75. The onset of hypotension and hemodynamic disturbances was not delayed in animals treated with dmTNFot, relative to those animals receiving wtTNFcr as might have been expected if the changes were due to endogenous TNFot production. Nevertheless, the present studies do not distinguish rigorously between responses due to exogenous dmTNFot administration and endogenous TNFot because of the variability in the onset of clinical symptoms or signs. Furthermore, if p55 receptors were fully occupied by dmTNFot, then endogenous baboon TNFc~ is competed at p55 and would bind with some preference to the p75 receptor. Thus, the relatively low concentrations of endogenous TNFot might have disproportionate activities and elicit toxic host responses equivalent to higher TNFot concentrations.
Based on in vitro studies, distinct functions have been attributed to TNFot binding to these two TNF receptor types in various cells. However, the significance of TNFc~ in vivo, like that of other cytokines, cannot be easily deduced from individual tissue responses, but rather, should be understood from its integrated actions on the complex assembly of cells and organ systems in a living organism. The systemic toxicity of TNFoe, as reflected in hemodynamic changes and organ dysfunction, is undoubtedly the sum of responses by different cells in various organs.
It has been proposed from the differing toxicities of mouse and human TNFc~ in mice that p55 selective agonists can be expected to have a lower systemic toxicity than wild-type TNFot. This hypothesis has not been confirmed in this study. In fact, the results of this study are more consistent with the conclusion of Pfeffer et al. (15) who demonstrated that p55-deficient mice sensitized with D-galactosamine were tolerant of endotoxic shock. Furthermore, Rothe et al. (16) demonstrated that p55-deficient mice are insensitive to TNF toxicity, although they remain susceptible to the lethal effects of LPS in the absence of D-galactosamine sensitization. Finally, the fact that TNFc~ induction of endothelial cdl adhesion molecules, which must be considered part of systemic toxicity, is under dominant p55 control (8) also argues that p55 selective agonists cannot be completely devoid of systemic toxicity.
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